Figure 5.

A: High [⁸⁹Zr]Zr-Df-IAB22M2C uptake in the bone marrow was observed in the majority of the patients with ICT pretreatment, whereas patients without ICT pretreatment exhibited relatively low [⁸⁹Zr]Zr-Df-IAB22M2C uptake in the bone marrow. B: A high variability of splenic [⁸⁹Zr]Zr-Df-IAB22M2C uptake was determined in our patient cohort independent of ICT pretreatment or therapy response. C: The ratio of spleen to liver [⁸⁹Zr]Zr-Df-IAB22M2C uptake was not directly correlated with previous ICT. Nevertheless, both patients with long-term remission (> one year remission under ICT; Patients 3 and 4) displayed a considerably high spleen-to-liver ratio.